Gonadotropin-releasing hormone (GnRH) antagonists for controlled ovarian stimulation (COS) were only recently introduced into China. The efficacy and safety of the GnRH antagonist ganirelix was assessed in a multicenter, controlled, open-label study, in which Chinese women were randomized to either ganirelix (n = 113) or a long GnRH agonist protocol of triptorelin (n = 120). The primary end point was the amount of recombinant follicle-stimulating hormone (rFSH) required to meet the human chorionic gonadotropin criterion (three follicles = 17 mm). The amount of rFSH needed was significantly lower for ganirelix (1272 IU) vs. triptorelin (1416 IU; P < 0.001). Ongoing pregnancy rates per started cycle were 39.8% (ganirelix) and 39.2% (triptorelin). Although both treatments were well tolerated, cancellation due to risk of ovarian hyperstimulation syndrome (OHSS) was less frequent with ganirelix (1.8%) than triptorelin (7.5%) (P = 0.06). Less rFSH was needed in the ganirelix protocol than the long GnRH agonist protocol, with fewer reported cases of OHSS and similar pregnancy rates.
基金：
Merck; Sharp; Dohme & Co. (Whitehouse Station, NJ, USA)
Qiao Jie,Lu Guangxiu,Zhang H. W.,et al.A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates[J].GYNECOLOGICAL ENDOCRINOLOGY.2012,28(10):800-804.doi:10.3109/09513590.2012.665103.
APA：
Qiao, Jie,Lu, Guangxiu,Zhang, H. W.,Chen, Hua,Ma, Caihong...&Mannaerts, Bernadette.(2012).A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates.GYNECOLOGICAL ENDOCRINOLOGY,28,(10)
MLA：
Qiao, Jie,et al."A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates".GYNECOLOGICAL ENDOCRINOLOGY 28..10(2012):800-804
